(Q44206577)

30 November 2017

title

IL-6R distribution in normal human and cynomolgus monkey tissues (English)

1 reference

30 November 2017

Atsuhiko Kato

1

1 reference

30 November 2017

Takeshi Watanabe

2

1 reference

30 November 2017

Masaki Yamazaki

3

1 reference

30 November 2017

Toshiaki Deki

4

1 reference

30 November 2017

Masami Suzuki

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

30 October 2008

1 reference

Regulatory Toxicology and Pharmacology

30 November 2017

published in

1 reference

30 November 2017

volume

53

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

46-51

1 reference

IL-6 functions in cynomolgus monkeys blocked by a humanized antibody to human IL-6 receptor

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

The paradigm of IL-6: from basic science to medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

Inhibition of IL-6 for the treatment of inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.10.007

10.1016/J.YRTPH.2008.10.007

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference